Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies

Abstract This study evaluated the seroprevalence of poliovirus types 1, 2 and 3 antibodies and vaccination coverage in 780 subjects aged between 7 months and 39 years in Montevideo, Uruguay, where oral polio vaccine (OPV) is used. Antibody titers were measured and seroprotection rates and geometric...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-05, Vol.27 (20), p.2689-2694
Main Authors: Pírez, María Catalina, Olivera, Ignacio, Diabarboure, Hugo, Montano, Alicia, Barañano, Raúl, Badía, Federica, Bonnet, Marie-Claude
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age
Age Factors
Allergy and Immunology
Antibodies, Viral - blood
Antibody persistence
Applied microbiology
Biological and medical sciences
Child
Child, Preschool
Drug dosages
Female
Fundamental and applied biological sciences. Psychology
Hospitals
Human viral diseases
Humans
Immunization
Infant
Infectious diseases
Laboratories
Male
Medical sciences
Microbiology
Oral polio vaccine
Pediatrics
Poliomyelitis
Poliomyelitis - immunology
Poliomyelitis - prevention & control
Poliovirus
Poliovirus Vaccine, Oral - immunology
Population
Public policy
Seroepidemiologic Studies
Seroprevalence
Uruguay
Vaccination - utilization
Vaccination coverage
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral diseases
Viral diseases of the nervous system
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This study evaluated the seroprevalence of poliovirus types 1, 2 and 3 antibodies and vaccination coverage in 780 subjects aged between 7 months and 39 years in Montevideo, Uruguay, where oral polio vaccine (OPV) is used. Antibody titers were measured and seroprotection rates and geometric mean titers (GMTs) were compared among four age groups. Vaccination histories were recorded from documents and interviews. Seroprotection rates ranged from 72% to 95% in children aged 7–23 months, 31–77% in 2–9-year olds, 14–45% in 10–19-year olds and 20–59.5% in 20–39-year olds. Seroprotection decreased significantly with increasing age ( p < 0.05). Polio vaccination coverage was >90% for the two youngest age groups. These results could help guide public policy decisions regarding polio vaccination, and support the use of inactivated polio vaccine following cessation of OPV.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.02.042